Can Zofran (ondansetron) cause hypokalemia?

Ondansetron (Zofran) and Hypokalemia

Yes, ondansetron (Zofran) can cause hypokalemia as documented in its FDA drug label, though it is considered a less common adverse effect.

Evidence for Ondansetron-Induced Hypokalemia

• The FDA drug label for ondansetron specifically lists hypokalemia among its adverse reactions, categorizing it as occurring in less than 2% of patients 1
• A case report documents hypokalemia associated with ondansetron use in a 2-year-old patient with pre-B-cell ALL, suggesting a possible causal relationship 2
• Ondansetron belongs to the class of 5HT3 antagonists, which are noted in clinical guidelines to potentially increase the risk of QT prolongation, especially when combined with other conditions like hypokalemia 3

Mechanism and Risk Factors

• The exact mechanism by which ondansetron may cause hypokalemia is not fully established, but the case report suggests it may be related to the drug's effect on potassium homeostasis 2
• Risk may be increased when ondansetron is used in combination with other medications that can affect potassium levels 4
• Polypharmacy (use of >5 drugs) has been identified as a significant predictor of drug-induced hypokalemia, which may be relevant for patients receiving ondansetron along with multiple other medications 4

Clinical Significance and Monitoring

• Hypokalemia is particularly concerning when using ondansetron because:
  • Both ondansetron and hypokalemia independently can prolong the QT interval, potentially creating a dangerous synergistic effect 3
  • Guidelines specifically caution about using QT-prolonging drugs like ondansetron in patients with uncorrected hypokalemia 3
• Monitoring recommendations:
  • Consider checking potassium levels in patients on ondansetron who:
    • Are receiving multiple medications 4
    • Have conditions that may predispose to electrolyte abnormalities 5
    • Are experiencing symptoms that could indicate hypokalemia (muscle weakness, cardiac arrhythmias) 5

Management of Ondansetron-Associated Hypokalemia

• If hypokalemia develops:
  • Consider discontinuation of ondansetron if clinically appropriate 2
  • Provide potassium supplementation as needed 2
  • Evaluate for other potential causes of hypokalemia 4
  • Monitor cardiac status, particularly in patients with heart disease or other QT-prolonging medications 3

Prevention Strategies

• Consider baseline potassium measurement before initiating ondansetron in high-risk patients 5
• Avoid unnecessary polypharmacy when possible, as this increases risk of drug-induced electrolyte disturbances 4
• Be particularly cautious when combining ondansetron with other medications known to cause hypokalemia, such as diuretics 6

While ondansetron-induced hypokalemia is not among the most common adverse effects, clinicians should be aware of this potential complication, especially in patients with other risk factors for QT prolongation or electrolyte disturbances.